Literature DB >> 18310913

Structure-activity relationships of receptor binding of 1,4-dihydropyridine derivatives.

Daiki Takahashi, Luvsandorj Oyunzul, Satomi Onoue, Yoshihiko Ito, Shinya Uchida, Rahime Simsek, Miyase Gozde Gunduz, Chiat Safak, Shizuo Yamada.   

Abstract

The present study was undertaken to investigate binding activity of synthesized 1,4-dihydropyridine (1,4-DHP) derivatives (Compounds 1--124) to 1,4-DHP calcium channel antagonist receptors in rat brain. Sixteen 1,4-DHP derivatives inhibited specific (+)-[3H]PN 200-110 binding in rat brain in a concentration-dependent manner with IC50 value of 0.43 to 3.49 microM. Scatchard analysis revealed that compounds 54, 69, 85, like nifedipine, caused a significant increase in apparent dissociation constant (Kd) for (+)-[3H]PN 200-110, while compounds 68, 69 and 80 caused a significant decrease in maximal number of bindings sites (Bmax). These data suggest that compounds 68, 69 and 80 exert longer-acting antagonistic effects of 1,4-DHP receptors than compounds 54, 69 and 85. The structure-activity relationship study has revealed that 1) ester groups in 3- and 5-positions are the most effective, 2) the aryl group in the 4-position of 1,4-DHP ring is the basic requirement for optimal activity, 3) position and type of electron-withdrawing groups on phenyl group at position 4 would affect the receptor-binding activity. Furthermore, compound 58 exerted alpha1 receptor binding activity, being 1.6 times greater than 1,4-DHP receptors. Compounds 81, 84, 91, 94, 106, 108 and 109 showed significant binding of ATP-sensitive potassium (K ATP) channel, and the binding activities of compounds 81, 84, 108 and 109 were 1.6--3.8 times greater than the binding activity for 1,4-DHP receptors. Compounds 91 and 106 had similar binding activity for K ATP channel and 1,4-DHP receptors. In conclusion, the present study has shown that novel 1,4-DHP derivatives exert relatively high binding affinity to 1,4-DHP receptors and has revealed new aspect of structure-activity relationships of 1,4-DHP derivatives, especially hexahydroquinoline derivatives.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18310913     DOI: 10.1248/bpb.31.473

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  6 in total

1.  The effect of bromine scanning around the phenyl group of 4-phenylquinolone derivatives.

Authors:  Scott A Steiger; Anthony J Monacelli; Chun Li; Janet L Hunting; Nicholas R Natale
Journal:  Acta Crystallogr C Struct Chem       Date:  2014-07-31       Impact factor: 1.172

2.  Lithium Perchlorate-, Acetic Anhydride-, and Triphenylphosphine-assisted Multicomponent Syntheses of 4-Unsubstituted 2,5-Dioxooctahydroquinoline-3-carboxylates and 3-carbonitriles.

Authors:  Xingxian Gu; Gunda I Georg
Journal:  Tetrahedron       Date:  2013-09-05       Impact factor: 2.457

3.  Synthesis and SAR of b-annulated 1,4-dihydropyridines define cardiomyogenic compounds as novel inhibitors of TGFβ signaling.

Authors:  Dennis Schade; Marion Lanier; Erik Willems; Karl Okolotowicz; Paul Bushway; Christine Wahlquist; Cynthia Gilley; Mark Mercola; John R Cashman
Journal:  J Med Chem       Date:  2012-11-06       Impact factor: 7.446

4.  Antihypertensive effects of new dihydropyridine derivatives on phenylephrine-raised blood pressure in rats.

Authors:  Sara Rowghani Haghighi Fard; Ramin Miri; Ali Akbar Nekooeian
Journal:  Res Pharm Sci       Date:  2016-12

5.  Crystal structure of ethyl 4-[4-(di-methyl-amino)-phen-yl]-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexa-hydro-quinoline-3-carboxyl-ate.

Authors:  Scott A Steiger; Chun Li; Nicholas R Natale
Journal:  Acta Crystallogr E Crystallogr Commun       Date:  2018-09-11

6.  4-Pyridinio-1,4-Dihydropyridines as Calcium Ion Transport Modulators: Antagonist, Agonist, and Dual Action.

Authors:  Ilona Domracheva; Iveta Kanepe-Lapsa; Reinis Vilskersts; Imanta Bruvere; Egils Bisenieks; Astrida Velena; Baiba Turovska; Gunars Duburs
Journal:  Oxid Med Cell Longev       Date:  2020-03-27       Impact factor: 6.543

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.